Cartesian Therapeutics, Inc. Common Stock RNAC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T14:43:17.753Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T14:40:04.010599293Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T14:43:16.743773+00:00
Cartesian Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.24 | 661.5% | 57.3% | |||
| 25Δ | 5.73 | 591.3% | 50.0% | |||
| 30Δ | 6.21 | 521.0% | 42.7% | |||
| 35Δ | 6.70 | 450.8% | 35.3% | |||
| 40Δ | 7.19 | 380.6% | 28.0% | |||
| 45Δ | 7.60 | 328.3% | 22.4% | |||
| 50Δ | 7.89 | 307.2% | 19.9% | |||
| 55Δ | 8.17 | 286.2% | 17.5% | |||
| 60Δ | 13.78 | 689.0% | 149.0% | 8.45 | 265.1% | 15.0% |
| 65Δ | 8.50 | 546.9% | 68.2% | 8.73 | 244.0% | 12.5% |
| 70Δ | 6.66 | 452.0% | 40.2% | 9.02 | 222.9% | 10.1% |
| 75Δ | 5.43 | 364.8% | 21.6% | 9.30 | 201.9% | 7.6% |
| 80Δ | 9.58 | 180.8% | 5.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.24
- IV
- 661.5%
- B/E move
- 57.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.73
- IV
- 591.3%
- B/E move
- 50.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.21
- IV
- 521.0%
- B/E move
- 42.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.70
- IV
- 450.8%
- B/E move
- 35.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.19
- IV
- 380.6%
- B/E move
- 28.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.60
- IV
- 328.3%
- B/E move
- 22.4%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.89
- IV
- 307.2%
- B/E move
- 19.9%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.17
- IV
- 286.2%
- B/E move
- 17.5%
60Δ
- Pseudo strike
- 13.78
- IV
- 689.0%
- B/E move
- 149.0%
- Pseudo strike
- 8.45
- IV
- 265.1%
- B/E move
- 15.0%
65Δ
- Pseudo strike
- 8.50
- IV
- 546.9%
- B/E move
- 68.2%
- Pseudo strike
- 8.73
- IV
- 244.0%
- B/E move
- 12.5%
70Δ
- Pseudo strike
- 6.66
- IV
- 452.0%
- B/E move
- 40.2%
- Pseudo strike
- 9.02
- IV
- 222.9%
- B/E move
- 10.1%
75Δ
- Pseudo strike
- 5.43
- IV
- 364.8%
- B/E move
- 21.6%
- Pseudo strike
- 9.30
- IV
- 201.9%
- B/E move
- 7.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.58
- IV
- 180.8%
- B/E move
- 5.1%
Options history
No recorded observations
Biotechnology
ROIV
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that…
More →RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New…
More →RVMD
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is…
More →RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data…
More →RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic…
More →RZLT
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City,…
More →